HomeInsightsStock Comparison

Cipla Ltd vs Sun Pharmaceuticals Industries Ltd Stock Comparison

Cipla Ltd vs Sun Pharmaceuticals Industries Ltd Stock Comparison

Last Updated on: Aug 05, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1499 as of 05 Aug 15:30.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 22.1 on March 2025 . This represents a CAGR of 0.08% over 6 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 22.5 on March 2020 to 38.1 on March 2025 . This represents a CAGR of 9.18% over 6 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 116434 crore on March 2025 . This represents a CAGR of 22.71% over 6 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 84504 crore on March 2020 to ₹ 416392 crore on March 2025 . This represents a CAGR of 30.45% over 6 years.
  • The revenue of Cipla Ltd for the Jun '25 is ₹ 7216 crore as compare to the Mar '25 revenue of ₹ 7019 crore. This represent the growth of 2.8% The revenue of Sun Pharmaceutical Industries Ltd for the Jun '25 is ₹ 14315 crore as compare to the Mar '25 revenue of ₹ 13571 crore. This represent the growth of 5.48%.
  • The ebitda of Cipla Ltd for the Jun '25 is ₹ 2036 crore as compare to the Mar '25 ebitda of ₹ 1827 crore. This represent the growth of 11.47% The ebitda of Sun Pharmaceutical Industries Ltd for the Jun '25 is ₹ 3948 crore as compare to the Mar '25 ebitda of ₹ 3967 crore. This represent the decline of -0.48%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1292 crore over 9 quarters. This represents a CAGR of 12.23% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2013 crore to ₹ 2302 crore over 9 quarters. This represents a CAGR of 6.16% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.05 % on March 2025 . This represents a CAGR of 9.87% over 6 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 29.89 % on March 2020 to 89.64 % on March 2025 . This represents a CAGR of 20.09% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Sun Pharmaceutical Industries Ltd

  • Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
  • The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
  • It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
  • The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

Cipla Ltd News Hub

News

Cipla updates on USFDA cGMP inspection of its Bommasandra unit

Cipla announced that the United States Food and Drug Administration has classified the cur...

Read more

05 Aug 2025 09:46

News

Cipla's Bengaluru facility receives VAI classification from USFDA

The classification was communicated to the company via email on 4 August 2025. The inspect...

Read more

05 Aug 2025 14:05

News

Cipla gains after Q1 PAT rises 10% YoY to Rs 1,298 crore

Profit before tax (PBT) stood at Rs 1,769.93 crore in Q1 FY26, marking an 9.84% increase f...

Read more

25 Jul 2025 15:25

News

Cipla to conduct board meeting

Cipla will hold a meeting of the Board of Directors of the Company on 25 July 2025. Powere...

Read more

02 Jul 2025 10:19

News

Cipla allots 43,396 equity shares under ESOP

Cipla has allotted 43,396 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

27 Jun 2025 11:02

News

Cipla Ltd spurts 0.42%, up for fifth straight session

Cipla Ltd is up for a fifth straight session today. The stock is quoting at Rs 1517.2, up ...

Read more

11 Jun 2025 13:00

Sun Pharmaceutical Industries Ltd News Hub

News

Sun Pharma drops after Q1 PAT slips 20% YoY to Rs 2,279 cr

The drop in profit was primarily due to a one-time exceptional charge of Rs 818 crore duri...

Read more

31 Jul 2025 15:46

News

Sun Pharmaceutical Industries Ltd spurts 0.66%, up for five straight sessions

Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is qu...

Read more

29 Jul 2025 13:00

News

Sun Pharma announces top-line results of tildrakizumab 100 mg Phase 3 studies

Sun Pharmaceutical Industries announced top-line results from two Phase 3 clinical studies...

Read more

21 Jul 2025 09:05

News

Sun Pharmaceutical Industries Ltd spurts 2.56%, rises for third straight session

Sun Pharmaceutical Industries Ltd rose for a third straight session today. The stock is qu...

Read more

15 Jul 2025 13:05

News

Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp

The drug is indicated for the treatment of alopecia areata ' a condition in which the immu...

Read more

15 Jul 2025 15:41

News

Sun Pharmaceutical Industries launches LEQSELVI' (deuruxolitinib) 8 mg tablets in United States

Sun Pharmaceutical Industries announced LEQSELVI' (deuruxolitinib) 8 mg tablets is now ava...

Read more

14 Jul 2025 16:48

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Sun Pharmaceutical Industries Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Sun Pharmaceutical Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Cipla Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Cipla Ltd is 121,102 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 391,607 Cr

What are the key factors driving the stock performance of Cipla Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Cipla Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Sun Pharmaceutical Industries Ltd?

As of August 5, 2025, the Cipla Ltd stock price is INR ₹1499.25. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1632.15.

How do dividend payouts of Cipla Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Cipla Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions